Autologous lymphapheresis for the production of chimeric antigen receptor T cells

• DOI: 10.1111/trf.14003
• Publication Date: 2017-02-25T03:56:52Z
• Authors: Elizabeth S. Allen; David F. Stroncek; Jiaqiang Ren; Anne F. Eder; Kamille A. West; Terry J. Fry; Daniel W. Lee; Crystal L. Mackall; Cathy Conry‐Canti...
• Keywords: Leukapheresis; Peripheral blood lymphocyte

BACKGROUND The first step in manufacturing chimeric antigen receptor (CAR) T cells is to collect autologous CD3+ lymphocytes by apheresis. Patients, however, often have leukopenia or other disease‐related complications. We evaluated the feasibility of collecting adequate numbers cells, risk factors for inadequate collections, and rate adverse events. STUDY DESIGN AND METHODS Apheresis lymphocyte collections from patients participating three CAR T‐cell clinical trials were reviewed. Collections performed on COBE Spectra experienced nurses, with goal obtaining a minimum 0.6 × 10 9 target 2 cells. Preapheresis peripheral blood counts, apheresis parameters, product cell counts analyzed. RESULTS Of 71 69 (97%) achieved 55 (77%) target. Before apheresis, 16 yields below had significantly lower proportions absolute circulating higher blasts NK than those who (470 6 lymphocytes/L vs. 1340 lymphocytes/L, p = 0.008; 349 cells/L 914 cells/L, 0.001; 17.6% 4.55% blasts, 0.029). Enrichment compared occurred four patients, including two whose did not yield number complications 11 (15%) and, one exception, easily managed clinic. CONCLUSIONS In most undergoing therapy, leukapheresis well tolerated, are collected.